JPRN-UMIN000003215
Recruiting
Phase 2
A Phase II Study for the efficacy and safety of Erlotinib for Patients previously treated Non-small cell Lung Cancer Patients with EGFR Mutations - A Phase II Study for the efficacy and safety of Erlotinib for Patients previously treated Non-small cell Lung Cancer Patients with EGFR Mutations
Fujita Health Universty Hospital Division of Respirology and Allergology0 sites28 target enrollmentFebruary 20, 2010
Conditionson-small cell lung cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- on-small cell lung cancer
- Sponsor
- Fujita Health Universty Hospital Division of Respirology and Allergology
- Enrollment
- 28
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Active infection (fever) 2\)Cases with past history of EGFR\-TKI 3\)Presence of active interstitial lung disease or pulmonary fibrosis 4\)Patients with massive pleural or prericardial effusion or ascites 5\)Patients with uncontrollable complications 6\)Patients with active double cancer 7\)Pregnancy or lactation. 8\)Patients whose participation in the trial is judged to be inappropriate by the attending doctor.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
A study to test an oral combination of letrozole and everolimus for patients with advanced lung cancer who have progressed on first line chemotherapy.on Small Cell lung cancerNon Small Cell lung cancerCancer - Lung - Non small cellACTRN12607000218493Dept of Medical Oncology, Royal Adelaide Hospital20
Completed
Phase 1
Evaluation of efficacy and safety of Ebola vaccine iEvac-Z in humaJPRN-jRCTs031190118Koga Michiko30
Not yet recruiting
Phase 2
Ayurvedic treatment for pain, swelling and stiffness in all jointsHealth Condition 1: M258- Other specified joint disordersCTRI/2021/03/031630Shree jagadguru gavisidheswara ayurvedic medical college postgraduate studies and research center
Not yet recruiting
Phase 2
A phase 2 Study of the efficay and safty of erlotinib therapy for 3/4 stage EGFR gene mutation positive EGFR-TKI untreated non-small cell lung cancerJPRN-UMIN000011986Itabashi central medical center21
Completed
Phase 1
Phase I/II study on the safety and efficacy of repeated administration of FIT039 transdermal patch for verrucas caused by human papilloma-virusPhase I/II study on the safety and therapeutic efficacy of repeated administration of FIT039 transdermal patch on verrucas caused by human papillomavirusJPRN-UMIN000029695Department of Dermatology, Kyoto University Hospital44